LCL-521 is an inhibitor of acid ceramidase.1,2 It inhibits acid ceramidase activity in MCF-7 breast cancer cell lysates when used at a concentration of 1 ?M.1 LCL-521 (1 and 10 ?M) decreases sphingosine levels in MCF-7 cells. It inhibits the proliferation of MCF-7 cells (IC50 = 7.46 ?M) and induces cell cycle arrest at the G1 phase when used at a concentration of 2.5 ?M.2
1.Bai, A., Szulc, Z.M., Bielawski, J., et al.Targeting (cellular) lysosomal acid ceramidase by B13: Design, synthesis and evaluation of novel DMG-B13 ester prodrugsBioorg. Med. Chem.22(24)6933-6944(2014) 2.Bai, A., Mao, C., Jenkins, R.W., et al.Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidasePLoS One12(6)e0177805(2017)